1H-Pyrrole-3-Carboxylic Acid, 5-Formyl-2,4-Dimethyl-, Ethyl Ester

Heterocyclic Scaffold Construction in Kinase Inhibitor Discovery: Aldehyde-Driven Annulation Cascades

The 5-formyl substituent on the pyrrole nucleus enables a well-documented intramolecular Knoevenagel-Heck cascade with ortho-bromo benzylamines, generating pyrrolo[3,2-c]quinoline cores that have been exploited as ATP-competitive inhibitors of vascular endothelial growth factor receptor 2 (VEGFR2) and platelet-derived growth factor receptor (PDGFR). In a representative process-scale synthesis, the ester aldehyde undergoes reductive amination with 3-bromo-4-methoxybenzylamine in 1,2-dichloroethane using sodium triacetoxyborohydride (1.5 equiv.), followed by palladium(II) acetate (5 mol%), triphenylphosphine (10 mol%), and potassium carbonate in dimethylacetamide at 110 °C for 16 h. The telescoped sequence avoids isolation of the intermediate secondary amine, which exhibits limited stability under atmospheric oxygen and must be handled under a nitrogen blanket in multi-purpose kilo-lab suites equipped with ATEX-rated agitated nutsche filter dryers.

Addition levels of the pyrrole aldehyde ester in the medicinal chemistry route typically correspond to 1.0–1.2 equivalents relative to the benzylamine component, with the excess charged to compensate for aldehyde oxidation losses estimated at 3–5 % during reagent transfers. Final active pharmaceutical ingredient (API) synthesis steps are governed by ICH Q7 Section 11.1 (General Controls) and require demonstrated control of genotoxic impurities—specifically, the 5-formyl pyrrole ester is itself flagged as a potential mutagenic impurity according to an in silico assessment using DEREK Nexus v6.1, and its residual level in the API must be controlled below the threshold of toxicological concern of 1.5 μg/day per ICH M7(R2). The downstream process for the free acid hydrolysed intermediate utilises lithium hydroxide monohydrate in tetrahydrofuran/water (3:1 v/v) at 45 °C for 4 h, then pH adjustment to 2.5 with hydrochloric acid to precipitate the carboxylic acid, which is isolated by centrifugation and dried under vacuum (40 °C, 10 mbar) to residual water ≤0.5 % by Karl Fischer titration. This acid intermediate is then coupled to a range of heterocyclic amines to produce a focussed library of kinase inhibitors evaluated in cellular proliferation assays against HCT-116 and MCF-7 cell lines.

When the Ethyl Ester Serves as a Latent Protecting Group in Porphyrin and Chlorin Syntheses for Photodynamic Therapy

In the MacDonald [2+2] porphyrin synthesis route toward meso-substituted chlorin photosensitisers, 1H-pyrrole-3-carboxylic acid, 5-formyl-2,4-dimethyl-, ethyl ester is deliberately employed as a dipyrromethane precursor wherein the ethyl ester functions as a masked carboxylic acid that remains intact during the acidic condensation and oxidative aromatisation steps, then is unmasked post-macrocyclisation by saponification followed by coupling to polyethylene glycol chains for improved tumour selectivity. The condensation is run in anhydrous dichloromethane under a stream of dry argon with boron trifluoride diethyl etherate (0.3 equiv. per pyrrole ring) at −10 °C, followed by DDQ oxidation (2.2 equiv.) at ambient temperature over 45 min. Column chromatography on neutral alumina (activity grade III) eluting with dichloromethane/methanol (98:2) separates the desired porphyrinogen from chlorin contamination; the typical isolated yield of porphyrin after crystallisation from dichloromethane/methanol is 18–24 %, a range constrained by the inherent statistical distribution of pyrrole aldehyde self-condensation products.

The pharmaceutical compliance landscape for photodynamic therapy agents mandates adherence to the European Pharmacopoeia monograph 01/2023:3078 for porphyrin-based active substances, specifically the test for related substances by liquid chromatography (limit of individual unspecified impurity ≤0.10 %). Terminal sterilisation by gamma irradiation (25 kGy) is validated per ISO 11137-1:2006, with pre-sterilisation bioburden controlled below 100 CFU/g. Final dosage forms are lyophilised powders for reconstitution, wherein the chlorin active incorporates the hydrolysed pyrrole-carboxylic acid as the hydrophilic anchor; the ethyl ester precursor typically constitutes 35–42 wt% of the total raw material mass input into the GMP synthesis chain. Finished vials contain 15 mg or 75 mg of the chlorin, corresponding to patient-specific dosing protocols based on body surface area.

A less-documented but industrially significant application exploits the electron-deficient pyrrole nucleus as a building block for heterocyclic herbicides targeting protoporphyrinogen oxidase (PPO). When the 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester is subjected to a Hantzsch-type cyclocondensation with ethyl acetoacetate and ammonium acetate in refluxing ethanol, the resulting dihydropyridine-pyrrole hybrid undergoes Vilsmeier formylation at the pyrrole α-position followed by condensation with phenyl isocyanate to yield a bicyclic uracil analog. Field trials conducted under GLP conditions (OECD Series on Testing and Assessment No. 116) have evaluated the compound’s efficacy against Amaranthus retroflexus and Chenopodium album at application rates of 75–150 g ai/ha in pre-emergence corn. The ethyl ester moiety contributes to enhanced soil mobility (Koc 89–112 mL/g) relative to the free carboxylic acid, as determined per OECD Guideline 121 by HPLC batch equilibrium on five reference soils. Manufacturing of the formulated product—a 240 g/L emulsifiable concentrate—requires the active ingredient to be dissolved in a blend of aromatic hydrocarbon solvent (Solvesso 200 ND) and anionic/nonionic emulsifiers (calcium dodecylbenzene sulfonate + castor oil ethoxylate, 8 % w/w total), with the batch stirred under high-shear dispersion at 3000 rpm for 20 min to achieve a droplet size distribution with D90 ≤3.0 μm as measured by laser diffraction (Malvern Mastersizer 3000).

Regulatory compliance for the plant protection product follows Regulation (EC) 1107/2009, with the technical active substance specification requiring a minimum purity of 980 g/kg and limits on relevant impurities, including the hydrazine derivative (≤ 0.5 g/kg) arising from the synthetic route. Accelerated storage stability testing at 54 °C for 14 days (CIPAC MT 46.3) confirms less than 5 % degradation of the ester when packaged in fluorinated HDPE containers.

Anodic Interfacial Modifier in Perovskite Photovoltaic Stacks: Aldehyde-Driven Crosslinking on Nickel Oxide

On rigid inverted (p-i-n) perovskite solar cells employing nickel(II) oxide hole transport layers deposited by spin-coating onto indium tin oxide substrates, the pyrrole aldehyde ester has been introduced as a sub-nanometre-thick interfacial dipole modifier. The sacrificial aldehyde group forms a Schiff-base linkage with the amino-functionalised nickel oxide surface pre-treated with (3-aminopropyl)triethoxysilane vapour in a vacuum oven at 120 °C for 2 h, while the ester carbonyl coordinates to the perovskite precursor lead(II) iodide, retarding crystallisation kinetics and promoting a larger grain size (800–1200 nm) in the methylammonium lead iodide layer deposited atop. Addition ratio is controlled by dipping the NiO/APTES substrate into a 0.5 mM solution of the pyrrole ester in anhydrous chlorobenzene for 60 s under inert atmosphere (glovebox, H₂O <0.1 ppm, O₂ <0.1 ppm), then rinsing with neat chlorobenzene to remove physisorbed molecules, leaving a chemisorbed monolayer confirmed by X-ray photoelectron spectroscopy nitrogen 1s signal integration.

Device fabrication follows protocols aligned with the IEC 60904-1:2020 measurement standard for photovoltaic current-voltage characteristics: the final device stack ITO/NiO/interlayer/perovskite/PCBM/BCP/silver yields a geometrically defined active area of 0.0625 cm² using a metal shadow mask evaporated at 5 × 10⁻⁶ mbar. Inclusion of the pyrrole aldehyde ester interlayer has been reported to increase the open-circuit voltage by 40–65 mV and reduce hysteresis index to 4–7 % compared with 12–18 % for the unmodified control; however, published data for extended damp-heat stability (85 °C/85 % RH per IEC 61215-1:2021) is limited, and preliminary observations suggest delamination at the NiO interface beyond 500 h of exposure, making the configuration more suitable for research-grade optimisation rather than production module qualification. The ethyl ester variant is specifically preferred over the methyl ester for its lower volatility during high-vacuum physical vapour deposition pre-cleaning steps.

Physical handling of the compound across all processing environments requires strict moisture exclusion protocols. The material is received as a pale yellow crystalline solid (melting point 92–94 °C) in sealed aluminium-laminate bags under argon, and must be stored at 2–8 °C. Exposure to ambient relative humidity exceeding 40 % for periods beyond 30 min initiates surface hydration that introduces 0.8–1.2 % water by Karl Fischer, sufficient to interfere with the anhydrous BODIPY and porphyrin condensation reactions. At formulation scales above 10 kg, rotary cone vacuum dryers operating at 50 °C, 5 mbar for 12 h are employed to reduce water content to ≤0.1 % prior to charging.